ImmunoCellular Therapeutics, Ltd. (IMUC)

Oncology Corporate Profile

Stock Performance

0.3453
-0.0047

3 Month Stock History Chart

HQ Location

21900 Burbank Boulevard, 3rd Floor
Woodland Hills, CA 91367

Company Description

ImmunoCellular is a clinical-stage company that is focused on developing new therapeutics to fight cancer using the immune system. The Company's product pipeline includes peptide based vaccine to target cancer stem cells, cellular immunotherapies to target cancer associated antigens, and monoclonal antibodies to diagnose and treat several different cancers.

Website: http://www.imuc.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
ICT-107cancer antigen vaccineGlioblastoma Multiforme (GBM)III
ICT-121cancer stem cell antigen vaccineGlioblastoma Multiforme (GBM)I
ICT-140cancer stem cell antigen vaccineOvarian cancerI

View additional information on product candidates here »

Source: http://www.imuc.com

Recent News Headlines

ImmunoCellular Therapeutics Treats First Patient in ICT-107 Phase 3 Registrational Trial in Newly Diagnosed Glioblastoma

6/7/2016 07:33 pm

(ImmunoCellular) June 7, 2016 - ImmunoCellular Therapeutics, Ltd. today announced that the first patient has been treated in the phase 3 registrational trial of ICT-107, the Company's lead cancer immunotherapy product candidate, in newly diagnosed glioblastoma.

TSRI and JCVI Scientists Find Popular Stem Cell Techniques Safe

2/22/2016 11:04 am

(TSRI) Feb 19, 2016 - A new study led by scientists at The Scripps Research Institute (TSRI) and the J. Craig Venter Institute (JCVI) shows that the act of creating pluripotent stem cells for clinical use is unlikely to pass on cancer-causing mutations to patients.

ImmunoCellular Therapeutics Enters into a Sponsored Research Agreement with The University of Maryland, Baltimore to Pursue Multiple Enhancements of its Cancer Immunotherapy Platforms

1/27/2016 05:57 pm

(4-traders) Jan 27, 2016 - ImmunoCellular Therapeutics, Ltd. today announced it has entered into a sponsored research agreement with Eduardo Davila, PhD, Associate Professor of Microbiology and Immunology at the University of Maryland School of Medicine, and the University of Maryland, Baltimore.

ImmunoCellular Therapeutics Establishes Agreement with The Canadian Brain Tumour Consortium for ICT-107 Phase 3 Registrational Trial in Glioblastoma

12/14/2015 05:55 pm

(StreetInsider) Dec 14, 2015 - ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with a major Canadian cancer cooperative group, The Canadian Brain Tumour Consortium (CBTC), for the phase 3 registrational trial of its cancer immunotherapy ICT-107 in patients with newly diagnosed glioblastoma.

ImmunoCellular Therapeutics Establishes Agreement with Alliance Foundation Trials, LLC for ICT-107 Phase 3 Registrational Trial in Glioblastoma

12/7/2015 08:26 pm

(ImmunoCellular) Dec 7, 2015 - ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with a major cancer research group, Alliance Foundation Trials, LLC (AFT), for the phase 3 registrational trial of its cancer immunotherapy ICT-107 in patients with newly diagnosed glioblastoma.

ImmunoCellular Therapeutics Establishes Agreement with EORTC for ICT-107 Phase 3 Registrational Trial in Glioblastoma

12/1/2015 06:38 pm

(StreetInsider) Dec 1, 2015 - ImmunoCellular Therapeutics, Ltd. announced today the establishment of an agreement with the European Organisation for Research and Treatment of Cancer (EORTC) for the phase 3 registrational trial of ICT-107 in patients with newly diagnosed glioblastoma (GBM).

ImmunoCellular Therapeutics Presents Updated ICT-107 Phase 2 Survival and Immune Response Data at the Society for Neuro-Oncology Annual Meeting 2015

11/23/2015 05:33 pm

(ImmunoCellular) Nov 20, 2015 - ImmunoCellular Therapeutics, Ltd. announced the presentation today of recently updated overall survival (OS) results and immune response data from the phase 2 trial of ICT-107 in patients with newly diagnosed glioblastoma.

ImmunoCellular Therapeutics Presents Updated ICT-107 Phase 2 Survival and Immune Response Data at the Society for Neuro-Oncology Annual Meeting 2015

11/20/2015 05:32 pm

(ImmunoCellular) Nov 20, 2015 - ImmunoCellular Therapeutics, Ltd. announced the presentation today of recently updated overall survival (OS) results and immune response data from the phase 2 trial of ICT-107 in patients with newly diagnosed glioblastoma.

ImmunoCellular Therapeutics Enters into Sponsored Research Agreement with University of Texas MD Anderson Cancer Center to Advance Stem-to-T-Cell Program

11/12/2015 06:05 pm

(Yahoo! Finance) Nov 12, 2015 - ImmunoCellular Therapeutics, Ltd. today announced it has entered into a sponsored research agreement with Dr. Cassian Yee at the University of Texas MD Anderson Cancer Center.

ImmunoCellular Secures Grant for Clinical Trial of Glioblastoma

9/25/2015 04:57 pm

(Pharmaceutical Business Review) Sept 25, 2015 - The California Institute for Regenerative Medicine (CIRM) has awarded a $19.9m grant to ImmunoCellular Therapeutics to support the phase 3 clinical trial of ICT-107 in patients with newly diagnosed glioblastoma.

ImmunoCellular Therapeutics Issues Letter to Shareholders, Highlighting Progress on Advancing ICT-107 to Phase 3 Registrational Trial

8/24/2015 04:16 pm

(ImmunoCellular) Aug 21, 2015 - ImmunoCellular Therapeutics, Ltd. today issued the following letter to shareholders.

ImmunoCellular Therapeutics Reaches Agreement with FDA on Special Protocol Assessment (SPA) for ICT-107 Phase 3 Registrational Trial in Glioblastoma

8/13/2015 05:02 pm

(StreetInsider) Aug 13, 2015 - ImmunoCellular Therapeutics, Ltd. announced today that it has reached agreement with the US Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the phase 3 registrational trial of its cancer immunotherapy ICT-107 to treat patients with newly diagnosed glioblastoma.

ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma

7/6/2015 04:35 pm

(StreetInsider) July 6, 2015 - ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with Novella Clinical, to conduct the phase 3 registration trial of ICT-107 in patients with newly diagnosed glioblastoma.

ASCO Commends Dr. Harold Varmus’ Outstanding Leadership as NCI Director

3/5/2015 12:01 pm

(ASCO) Mar 5, 2015 - The American Society of Clinical Oncology (ASCO) is enormously grateful for the service and leadership of Harold Varmus, MD, as Director of the National Cancer Institute (NCI).

Brandicourt as Sanofi Chief to Focus on Taking Drugs to U.S.

2/20/2015 11:01 am

(Bloomberg) Feb 19, 2015 - Olivier Brandicourt, whose track record includes the introduction of the best-selling drug in history, takes the helm at Sanofi with the mandate of bringing new drugs to the U.S. after missteps led to his predecessor’s ouster.

Does Pharma Money Mix With Cash Receptors in Your Doctor’s Wallet?

2/9/2015 12:00 pm

(Wall Street Journal/Pharmalot blog) Feb 9, 2015 - In a mocking, but pointed segment on Last Week Tonight, comedian John Oliver recaps the controversy over marketing to doctors, which has embroiled the pharmaceutical industry in recent years.

Specialist Doctors Head for Exit as U.S. Shifts Payments

2/2/2015 06:04 am

(Bloomberg) Feb 2, 2015 - The Obama administration’s push to transform the way the U.S. pays for health care is splitting the medical profession, as family doctors embrace changes that oncologists, neurologists and other specialists are concerned will cause turmoil.

Merck Will No Longer Sell its Victrelis Hepatitis C Drug in the U.S.

1/21/2015 01:01 pm

(Wall Street Journal/Pharmalot blog) Jan 21, 2015 - Rival hepatitis C drugs from Merck and Vertex Pharmaceuticals made a big splash when they debuted in 2011, marking an advance in treatment of the liver disease and a lucrative new market segment.

ImmunoCellular Therapeutics Receives Positive Regulatory Feedback from European Medicines Agency on Advancing ICT-107 to Phase III Program

12/1/2014 05:58 pm

(ImmunoCellular Therapeutics) Dec 1, 2014 - ImmunoCellular Therapeutics, Ltd. today announced that the European Medicines Agency (EMA) has provided scientific advice supportive of advancing ICT-107 to a registrational phase III program in patients with newly diagnosed glioblastoma (GBM).

ImmunoCellular Therapeutics Presents Updated ICT-107 Phase II Data at the Society for Neuro-Oncology Annual Meeting 2014

11/14/2014 05:56 pm

(San Francisco Business Times) Nov 14, 2014 – Continued positive trends in overall survival and progression-free survival; phase 3 registration program anticipated to start 1H15; company to host conference call on Tuesday, November 18th.

Brain Tumor Community Pushes For Inclusion of Patient-Focused Endpoints in Future Clinical Trials

11/7/2014 06:02 am

(National Brian Tumor Society) Nov 6, 2014 - A recent workshop brought together leaders and stakeholders from the neuro-oncology, neurology, and clinical outcomes assessment fields to address the critical issue of incorporating patient-focused endpoints into future brain cancer clinical trials.

Roche CEO Rules Out Big Deals

9/17/2014 07:02 am

(Wall Street Journal) Sept 17, 2014 - Roche won't change its acquisition strategy following the recent spate of megadeals signed or abandoned in the pharmaceutical sector, Chief Executive Severin Schwan said in an interview.

Research Finds No Association Between Wearing a Bra and Breast Cancer

9/5/2014 06:00 am

(AACR) Sept 5, 2014 - A population-based case-control study found no association between bra wearing and increased breast cancer risk among postmenopausal women, according to research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

Allergan's Ozurdex Gets FDA Nod

6/30/2014 06:03 am

(Wall Street Journal) June 30, 2014 - Allergan Inc. said Monday that the U.S. Food and Drug Administration had approved its Ozurdex eye treatment, while reporting positive midstage results for other drugs in its pipeline.

ImmunoCellular Therapeutics Presents Updated ICT-107 Phase II Data in Patients with Newly Diagnosed Glioblastoma at the 2014 ASCO Annual Meeting

6/1/2014 11:42 pm

(ImmunoCellular) June 1, 2014 - ImmunoCellular Therapeutics, Ltd. announced that updated efficacy and safety data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107 in patients with newly diagnosed glioblastoma multiforme (GBM) were presented at the 2014 ASCO annual meeting in Chicago.

ImmunoCellular Therapeutics Presents Updated ICT-107 Phase II Data in Patients with Newly Diagnosed Glioblastoma at the 2014 ASCO Annual Meeting

6/1/2014 01:04 pm

(ImmunoCellular) June 1, 2014 - ImmunoCellular Therapeutics, Ltd. announced that updated efficacy and safety data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107 in patients with newly diagnosed glioblastoma multiforme (GBM) were presented at the 2014 ASCO annual meeting in Chicago.

ImmunoCellular Therapeutics Announces ICT-107 Phase II Data Abstract Accepted for Oral Presentation at the 2014 ASCO Annual Meeting

4/22/2014 04:51 pm

(San Francisco Business Times) Apr 21, 2014 - ImmunoCellular Therapeutics, Ltd. today announced that the abstract describing the Company's phase II trial of dendritic cell-based cancer vaccine ICT-107 in newly diagnosed glioblastoma (GBM) has been accepted for an oral presentation at the 2014 ASCO annual meeting in Chicago.

ImmunoCellular Therapeutics Announces ICT-107 Phase II Data Abstract Accepted for Oral Presentation at the 2014 ASCO Annual Meeting

4/22/2014 11:05 am

(San Francisco Business Times) Apr 21, 2014 - ImmunoCellular Therapeutics, Ltd. today announced that the abstract describing the Company's phase II trial of dendritic cell-based cancer vaccine ICT-107 in newly diagnosed glioblastoma (GBM) has been accepted for an oral presentation at the 2014 ASCO annual meeting in Chicago.

ImmunoCellular Therapeutics Receives Orphan Drug Status for ICT-107 in Glioblastoma in the European Union

2/25/2014 05:57 pm

(Yahoo! Finance) Feb 25, 2014 - ImmunoCellular Therapeutics, Ltd. announced that the European Medicines Agency (EMA) has granted orphan drug designation for ICT-107 for the treatment of patients with glioblastoma.

ImmunoCellular Therapeutics Receives Orphan Drug Status for ICT-107 in Glioblastoma in the European Union

2/25/2014 11:05 am

(Yahoo! Finance) Feb 25, 2014 - ImmunoCellular Therapeutics, Ltd. announced that the European Medicines Agency (EMA) has granted orphan drug designation for ICT-107 for the treatment of patients with glioblastoma.

Biotech Stock Mailbag: Inovio, Chelsea, Exelixis, Ariad, ImmunoCellular

1/3/2014 05:52 pm

(The Street) Jan 3, 2014 - Happy New Year and welcome back to the Biotech Stock Mailbag. Today marks the start of the eighth year for this column, which wouldn't be possible without your questions and comments. Thank you so much.

Biotech Stock Mailbag: Inovio, Chelsea, Exelixis, Ariad, ImmunoCellular

1/3/2014 11:05 am

(The Street) Jan 3, 2014 - Happy New Year and welcome back to the Biotech Stock Mailbag. Today marks the start of the eighth year for this column, which wouldn't be possible without your questions and comments. Thank you so much.

ImmunoCellular Therapeutics Announces First Patient Receives Vaccine in Phase I Trial of Cancer Vaccine ICT-121 in Recurrent Glioblastoma

1/2/2014 05:52 pm

(Immunocellular) Dec 23, 2013 - ImmunoCellular Therapeutics, Ltd. announced today that the first patient in the phase I clinical trial of ICT-121, a cancer vaccine targeting recurrent glioblastoma multiforme (GBM, or brain cancer), has received the vaccine.

ImmunoCellular Therapeutics Announces First Patient Receives Vaccine in Phase I Trial of Cancer Vaccine ICT-121 in Recurrent Glioblastoma

1/2/2014 11:05 am

(Immunocellular) Dec 23, 2013 - ImmunoCellular Therapeutics, Ltd. announced today that the first patient in the phase I clinical trial of ICT-121, a cancer vaccine targeting recurrent glioblastoma multiforme (GBM, or brain cancer), has received the vaccine.

Why Northwest Bio's DCVax Brain Tumor Vaccine Will Blow Up Just Like ImmunoCellular's ICT-107

12/18/2013 05:06 pm

(TheStreet) Dec 17, 2013 - Dendritic cancer vaccines are too weak to be effective.

Why Northwest Bio's DCVax Brain Tumor Vaccine Will Blow Up Just Like ImmunoCellular's ICT-107

12/18/2013 11:00 am

(TheStreet) Dec 17, 2013 - Dendritic cancer vaccines are too weak to be effective.

ImmunoCellular's Lead Product Misses Key Endpoint

12/12/2013 06:51 pm

(Wall Street Journal) Dec 12, 2013 - ImmunoCellular's leading candidate, a vaccine for brain cancer, didn't show a significant advantage in overall survival in a mid-stage study.

ImmunoCellular Therapeutics Phase II Study Demonstrates That Glioblastoma Patients Live Longer Without Disease Progression When Treated With ICT-107

12/12/2013 12:39 pm

(Benzinga) Dec 11, 2013 - ImmunoCellular Therapeutics, Ltd. announced that ICT-107, its dendritic cell-based vaccine, demonstrated a statistically significant increase in progression-free survival (PFS) in patients with newly diagnosed glioblastoma multiforme (GBM) in its randomized, placebo-controlled phase II trial.

ImmunoCellular's Lead Product Misses Key Endpoint

12/12/2013 12:05 pm

(Wall Street Journal) Dec 12, 2013 - ImmunoCellular's leading candidate, a vaccine for brain cancer, didn't show a significant advantage in overall survival in a mid-stage study.

ImmunoCellular Therapeutics Phase II Study Demonstrates That Glioblastoma Patients Live Longer Without Disease Progression When Treated With ICT-107

12/12/2013 06:03 am

(Benzinga) Dec 11, 2013 - ImmunoCellular Therapeutics, Ltd. announced that ICT-107, its dendritic cell-based vaccine, demonstrated a statistically significant increase in progression-free survival (PFS) in patients with newly diagnosed glioblastoma multiforme (GBM) in its randomized, placebo-controlled phase II trial.

Novel Drug Prevents Common Viral Disease in Stem-Cell Transplant Patients, Study Finds

9/27/2013 11:01 am

(Dana-Farber Cancer Institute) Sep 26, 2013 - A common, sometimes severe viral disease in patients receiving a transplant of donated stem cells can be prevented by a new drug given shortly after transplant, according to a study led by Dana-Farber Cancer Institute and Brigham and Women's Hospital researchers.

GSK Cancer Drug Combination Wins US Priority Review

9/16/2013 06:02 am

(Reuters) Sep 16, 2013 - A combination treatment from GlaxoSmithkline for melanoma, the deadliest form of skin cancer, has won priority review from U.S. regulators.

ImmunoCellular Therapeutics Announces Initiation of Phase I Trial of Cancer Vaccine ICT-121 in Recurrent Glioblastoma

7/30/2013 04:40 pm

(Yahoo! Finance) July 30, 2013 - ImmunoCellular Therapeutics, Ltd. today announced initiation of a phase I clinical trial of cancer vaccine ICT-121 as a potential treatment for patients with recurrent glioblastoma multiforme (GBM).

ImmunoCellular Therapeutics Announces Initiation of Phase I Trial of Cancer Vaccine ICT-121 in Recurrent Glioblastoma

7/30/2013 11:04 am

(Yahoo! Finance) July 30, 2013 - ImmunoCellular Therapeutics, Ltd. today announced initiation of a phase I clinical trial of cancer vaccine ICT-121 as a potential treatment for patients with recurrent glioblastoma multiforme (GBM).

ImmunoCellular Therapeutics Announces Recommendation of Data Monitoring Committee to Continue ICT-107 Phase II Trial Following Interim Analysis

6/10/2013 05:08 pm

(Daily Finance) June 7, 2013 - ImmunoCellular Therapeutics, Ltd. announced that the Data Monitoring Committee (DMC) has completed a pre-specified interim analysis of the ICT-107 phase II clinical trial in patients with newly diagnosed glioblastoma and recommended that the company continue the trial to completion.

ImmunoCellular Therapeutics Announces Recommendation of Data Monitoring Committee to Continue ICT-107 Phase II Trial Following Interim Analysis

6/10/2013 12:00 pm

(Daily Finance) June 7, 2013 - ImmunoCellular Therapeutics, Ltd. announced that the Data Monitoring Committee (DMC) has completed a pre-specified interim analysis of the ICT-107 phase II clinical trial in patients with newly diagnosed glioblastoma and recommended that the company continue the trial to completion.

Biotech Stock Mailbag: Dynavax, ImmunoCellular, Celldex and Medgenics

2/8/2013 06:27 pm

(TheStreet) Feb 8, 2013 - Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Biotech Stock Mailbag: Dynavax, ImmunoCellular, Celldex and Medgenics

2/8/2013 12:02 pm

(TheStreet) Feb 8, 2013 - Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Researchers Use New Molecular Inhibitors to Successfully Hit Difficult Cancer Target

2/7/2013 12:02 pm

(Cincinnati Children's) Feb 6, 2013 - Early laboratory tests are the first to successfully use an experimental molecular therapy to block a hard-to-target part of a protein complex linked to several types of invasive cancer.

FDA Drug Safety Communication: Safety Review Update of Cancer Drug Revlimid (Lenalidomide) and Risk of Developing New Types of Malignancies

11/26/2012 12:04 pm

(FDA) Nov 23, 2012 - This update is in follow-up to the FDA Drug Safety Communication: Ongoing safety review of Revlimid (lenalidomide) and possible increased risk of developing new malignancies.